Current Alzheimer Research - Volume 18, Issue 6, 2021

Early pharmacoepidemiological studies suggested that Proton Pump Inhibitors (PPIs) might increase the risk of Alzheimer’s Disease (AD) and non-AD related dementias. These findings were supported by preclinical studies, specifically stressing the proamyloidogenic and indirect anticholinergic effects of PPIs. However, further large-scale pharmacoepidemiological studies showed inconsistent results on the association between P Read More

Background: In Alzheimer’s disease (AD), and amyloid models such as the 5XFAD mouse, butyrylcholinesterase (BChE) is associated with β-amyloid (Aβ) plaques and has unique biochemical features which distinguish it from that found in neurons. It has been suggested that BChE associated with Aβ plaques may be involved in the maturation of this structure and thus disease progression. Objective: Currently, it is unknown whether Read More

Background: The determinants of the progressive decrement of cognition in normal aging are still a matter of debate. Alzheimer disease (AD)-signature markers and vascular lesions, but also psychological variables such as personality factors, are thought to have an impact on the longitudinal trajectories of neuropsychological performances in healthy elderly individuals. Objective: The current research aimed to ide Read More

Background: Education could offer a protective effect on cognition in individuals with Subjective Cognitive Decline (SCD), which is considered to be the early stage of Alzheimer’s Disease (AD). However, the effect of education on cognition in SCD individuals with SCD-plus features is not clear. Objective: The aim of the study was to explore the effect of education on cognition in SCD individuals with SCD-plus features. Methods: A Read More

Background: The role of nigrostriatal dopaminergic neurons degeneration is well established in the pathophysiology of Parkinson’s disease. However, it is unclear if and how the degeneration of the dopamine pathways affects the manifestation of the neuropsychiatric symptoms (NPS) of Parkinson’s Disease (PD). Dopamine transporter (DAT) imaging, a technique to measure the reduction in dopamine transporters is incre Read More

Background: Alzheimer’s disease (AD) leads to progressive neuronal loss and cognitive and behavioral decline in the aging population. Matrix metalloproteinases (MMPs) and associated tissue inhibitors of metalloproteinases (TIMPs) are involved in remodeling the extracellular matrix. Amyloid beta-42 interrupts the integrity of the neurovascular unit and induces a toxic reaction affecting neurons. Objective: This study in Read More

Objective: Numerous electroencephalography (EEG) studies focus on the alteration of electrical activity in patients with Alzheimer’s Disease (AD), but there are no consistent results especially regarding functional connectivity. We supposed that the weighted Phase Lag Index (w- PLI), as phase-based measures of functional connectivity, may be used as an auxiliary diagnostic method for AD. Methods: We enrolled 30 patients wit Read More

Background: A significant proportion of patients with clinically diagnosed Alzheimer’s Disease (AD) and an even higher proportion of patients with amnestic mild cognitive impairment (aMCI) do not show evidence of amyloid deposition on Positron Emission Tomography (PET) with amyloid-binding tracers such as 11C-labeled Pittsburgh Compound B (PiB). Objective: This study aimed to identify clinical, neuropsychological an Read More